TIDMABC
RNS Number : 9945Y
ABCAM PLC
12 September 2022
ABCAM PLC
Appointment of Non-Executive Director
12 September 2022, Cambridge, UK - Abcam plc (AIM: ABC; Nasdaq:
ABCM) ("Abcam", "Company"), a global leader in the supply of life
science research tools, is pleased to announce the appointment of
Luba Greenwood as a non-executive Director with immediate
effect.
Luba's experiences focus on business development and strategy.
She is a veteran biotech, pharmaceutical, tech, and life sciences
investor and company builder. Luba has held a number of senior
leadership and board positions in the healthcare industry.
Currently, she serves as the managing partner of the Dana Farber
Cancer Institute Venture Fund, Binney Street Capital (BSC), which
she has built and launched. Luba is also the CEO of Kojin
Therapeutics, a BSC portfolio company. Her previous experience
includes increasing levels of responsibility at Google Life
Sciences, Verily and F. Hoffman-La Roche.
Luba has extensive board experience, and currently serves on the
board of directors of the following private institutions: MassBio,
BenchSci, and In8Bio, Inc.
Peter Allen, Chairman of Abcam said: "I am delighted to welcome
Luba to the Board of Abcam. Luba has had a distinguished career and
her experience and expertise, particularly her understanding of
Life Sciences, Technology and Healthcare will be a valuable asset
to the Company as we continue to partner in this area and work
towards our long-term growth plans."
Following Luba's appointment, the composition of each of the
Board Committees is confirmed as follows:
Board Committee Membership
Nomination Committee Peter Allen (Chair)
Mara Aspinall
Giles Kerr
==========================
Remuneration Committee Sally W. Crawford (Chair)
Mara Aspinall
Peter Allen
Giles Kerr
Mark Capone
==========================
Audit and Risk Committee Giles Kerr (Chair)
Mara Aspinall
Sally W. Crawford
==========================
AIM Rules disclosures
Luba Greenwood (age 43) holds or has held directorships in the
five years preceding her appointment at Abcam as follows:
Current Directorships Previous Directorships
(last five years)
Kojin Therapeutics, Inc. Entrinsic Bioscience, LLC
=============================
Massachusetts Biotechnology Council, Luca Biologics Inc.
Inc.(MassBio)
=============================
Scinapsis Analytics, Inc. (BenchSci) Brooklyn Immunotherapeutics,
Inc
=============================
OS Acquisition Corp. (OS Fund) Falcon Ridge Partners, LLC
=============================
In8Bio, Inc. Dana Point Advisors, LLC
=============================
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
For further information, please contact:
Abcam + 44 (0) 1223 696 000
Marc Perkins, Company Secretary
Tommy J. Thomas, CPA, Vice President, Investor Relations
Numis - Nominated Advisor & Joint Corporate Broker + 44 (0) 20 7260 1000
Freddie Barnfield / Duncan Monteith
Morgan Stanley - Joint Corporate Broker + 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting + 44 (0) 20 3727 1000
Ben Atwell / Lydia Jenkins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent program of customer reviews and
datasheets, combined with industry-leading validation initiatives,
gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
has served customers in more than 130 countries. Abcam's ordinary
shares are listed on the London Stock Exchange (AIM: ABC) and its
American Depositary Shares (ADSs) trade on the Nasdaq Global Market
(Nasdaq: ABCM).
For more information, please visit www.abcam.com or
www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation,
statements regarding Abcam's portfolio and ambitions, expected
performance for second half 2021, as well as statements that
include the words "expect," "intend," "plan," "believe," "project,"
"forecast," "estimate," "may," "should," "anticipate" and similar
statements of a future or forward-looking nature. Forward-looking
statements are neither promises nor guarantees, but involve known
and unknown risks and uncertainties that could cause actual results
to differ materially from those projected, including, without
limitation: a regional or global health pandemic, including the
novel coronavirus ("COVID-19"), which has adversely affected
elements of our business, could severely affect our business,
including due to impacts on our operations and supply chains;
challenges in implementing our strategies for revenue growth in
light of competitive challenges; developing new products and
enhancing existing products, adapting to significant technological
change and responding to the introduction of new products by
competitors to remain competitive; failing to successfully identify
or integrate acquired businesses or assets into our operations or
fully recognize the anticipated benefits of businesses or assets
that we acquire; if our customers discontinue or spend less on
research, development, production or other scientific endeavours;
failing to successfully use, access and maintain information
systems and implement new systems to handle our changing needs;
cyber security risks and any failure to maintain the
confidentiality, integrity and availability of our computer
hardware, software and internet applications and related tools and
functions; failing to successfully manage our current and potential
future growth; any significant interruptions in our operations; if
our products fail to satisfy applicable quality criteria,
specifications and performance standards; failing to maintain our
brand and reputation; our dependence upon management and highly
skilled employees and our ability to attract and retain these
highly skilled employees; and the important factors discussed under
the caption "Risk Factors" in Abcam's prospectus pursuant to Rule
424(b) filed with the U.S. Securities and Exchange Commission
("SEC") on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFZGGLKLMGZZM
(END) Dow Jones Newswires
September 12, 2022 02:01 ET (06:01 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Dec 2023 to Dec 2024
